ALTEOGEN Inc (196170) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ALTEOGEN Inc (196170) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩16.56 Billion ≈ $11.22 Million USD) by net assets (₩547.25 Billion ≈ $370.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ALTEOGEN Inc (196170) total market value for the company's overall valuation and market capitalisation.
ALTEOGEN Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how ALTEOGEN Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ALTEOGEN Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALTEOGEN Inc ranked by their cash flow conversion efficiency. Explore 196170 operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baxter International Inc
NYSE:BAX
|
0.046x |
|
Power Finance Corporation Limited
NSE:PFC
|
-0.050x |
|
Xian LONGi Silicon Materials Corp
SHG:601012
|
0.045x |
|
TAISEI CORP. ADR/ 1/4
F:TKK
|
N/A |
|
SON.HO.UN.ADR 1/5 SF -05
F:PHBA
|
N/A |
|
DT Midstream Inc
NYSE:DTM
|
0.060x |
|
Invesco Plc
NYSE:IVZ
|
0.016x |
|
Pro Medicus Ltd
AU:PME
|
0.178x |
Annual Cash Flow Conversion Efficiency for ALTEOGEN Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of ALTEOGEN Inc from 2014 to 2025. View ALTEOGEN Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩454.44 Billion ≈ $307.97 Million |
₩124.13 Billion ≈ $84.12 Million |
0.273x | +41.14% |
| 2024-12-31 | ₩274.09 Billion ≈ $185.75 Million |
₩53.04 Billion ≈ $35.95 Million |
0.194x | +468.44% |
| 2023-12-31 | ₩147.84 Billion ≈ $100.19 Million |
₩-7.77 Billion ≈ $-5.26 Million |
-0.053x | +56.29% |
| 2022-12-31 | ₩148.76 Billion ≈ $100.81 Million |
₩-17.87 Billion ≈ $-12.11 Million |
-0.120x | -73.66% |
| 2021-12-31 | ₩136.73 Billion ≈ $92.66 Million |
₩-9.46 Billion ≈ $-6.41 Million |
-0.069x | -700.12% |
| 2020-12-31 | ₩131.16 Billion ≈ $88.89 Million |
₩1.51 Billion ≈ $1.02 Million |
0.012x | -91.17% |
| 2019-12-31 | ₩69.98 Billion ≈ $47.43 Million |
₩9.13 Billion ≈ $6.19 Million |
0.131x | +195.42% |
| 2018-12-31 | ₩66.63 Billion ≈ $45.15 Million |
₩-9.11 Billion ≈ $-6.18 Million |
-0.137x | -25.37% |
| 2017-12-31 | ₩39.85 Billion ≈ $27.00 Million |
₩-4.35 Billion ≈ $-2.95 Million |
-0.109x | -56.21% |
| 2016-12-31 | ₩45.23 Billion ≈ $30.65 Million |
₩-3.16 Billion ≈ $-2.14 Million |
-0.070x | -218.91% |
| 2015-12-31 | ₩38.55 Billion ≈ $26.13 Million |
₩2.26 Billion ≈ $1.53 Million |
0.059x | +73.87% |
| 2014-12-31 | ₩35.82 Billion ≈ $24.28 Million |
₩1.21 Billion ≈ $820.03K |
0.034x | -- |
About ALTEOGEN Inc
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more